1.88
-0.18(-8.74%)
Currency In USD
| Previous Close | 2.06 |
| Open | 2.06 |
| Day High | 2.07 |
| Day Low | 1.85 |
| 52-Week High | 5.55 |
| 52-Week Low | 0.83 |
| Volume | 1.91M |
| Average Volume | 1.27M |
| Market Cap | 117.03M |
| PE | -1.19 |
| EPS | -1.58 |
| Moving Average 50 Days | 3.38 |
| Moving Average 200 Days | 2.01 |
| Change | -0.18 |
If you invested $1000 in Pyxis Oncology, Inc. (PYXS) since IPO date, it would be worth $142.42 as of January 14, 2026 at a share price of $1.88. Whereas If you bought $1000 worth of Pyxis Oncology, Inc. (PYXS) shares 3 years ago, it would be worth $1,261.74 as of January 14, 2026 at a share price of $1.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+
Pyxis Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcomi
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
GlobeNewswire Inc.
Oct 13, 2025 8:05 PM GMT
Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell